Relmada Therapeutics (RLMD) Interest Expenses (2012 - 2026)

Relmada Therapeutics (RLMD) has 15 years of Interest Expenses data on file, last reported at $37.9 million in Q1 2026.

• On a quarterly basis, Interest Expenses rose 79405.86% year-over-year to $37.9 million in Q1 2026; TTM through Mar 2026 was $37.9 million, a 27830.69% increase from a year earlier, with the FY2025 full-year figure at $6.9 million, up 5011.1% from the prior year.
• Interest Expenses for Q1 2026 stood at $37.9 million, up from $25165.0 in the prior quarter.
• Over the last five years, Interest Expenses for RLMD reached as high as $37.9 million in Q1 2026 and fell as low as $22182.0 in Q4 2023.
• Historically, Interest Expenses has averaged $4.6 million across 5 years, with a median of $44100.0 in 2023.
• Across the five-year window, Interest Expenses slumped 99.69% in 2025 and soared 79405.86% in 2026, its largest moves.
• Year by year, Interest Expenses stood at $417998.0 in 2022, then slumped by 94.69% to $22182.0 in 2023, then advanced by 26.22% to $27998.0 in 2024, then decreased by 10.12% to $25165.0 in 2025, then jumped by 150602.55% to $37.9 million in 2026.
• Per Business Quant data, the three most recent Interest Expenses figures were $37.9 million in Q1 2026, $25165.0 in Q4 2025, and $47700.0 in Q1 2025.